BioStrategies LC

This week our Senior Scientist Tianhong Yang ​is attending the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles CA. We are very excited to share our research and learn the advances in the gene therapy field.

BioStrategies scientists presented at this year’s in Orlando, FL, the annual research conference dedicated to lysosomal diseases. Research updates and new developments on our MPSI, MPSIIIA and GM1 programs were shared during two oral presentations and 5 poster presentations. Follow us on LinkedIn for latest updates. https://www.linkedin.com/company/biostrategies/

We are pleased to announce our most recent publication in collaboration with Dr. Alessandra d'Azzo at St. Jude Children's Research Hospital.
Abstract: https://www.mdpi.com/2073-4409/11/16/2579
PDF Version: https://www.mdpi.com/2073-4409/11/16/2579/pdf

Our first gene therapy phase I grant awarded! Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS

Good luck to Carmela Unnold She worked at Biostrategies for 5 years while working on her Bachelor degree in Biotechnology. She got accepted in a Ph.D. program in Molecular Biology at Washington University School of Medicine , St. Louis MO. We know you will have a bright and successful future. Thank you for your contributions to the company.

2014 Research Initiative Grant by National Tay-Sachs & Allied Diseases Association, Inc. (http://www.ntsad.org/index.php/research-we-fund/2014-research-grant)

NTSAD - 2014 Research Grant 2014 Research Initiative Grant Details Last Updated: Friday, 25 July 2014 15:55 David Radin, PhD, Principal Investigator BioStrategies, LC "Lectin-assisted transnasal delivery of corrective enzyme for GM1 gangliosidosis" The grant is a two-year $80,000 milestone-based grant. BioStrategies LC is a…

Congratulations to Dr. Carole Cramer: ABI 2014 Established Investigator of the Year Award

MPS 2014-Brazil

MPS 2014 at Brazil

Please follow us on twitter

This Tibbetts Award SBIR nomination highlights twenty years of successful SBIR research led by the team of Drs. David Radin and Carole Cramer, who have pioneered R&D leading to the introduction of bioengineered plants for manufacturing human therapeutic proteins. Their core innovation was achieved during their first SBIR award from NIH in 1993 which demonstrated that the normal gene for a human enzyme responsible for a rare genetic disease called Gauchers disease could be transformed into into plants and expressed to produce a bioactive human enzyme. This technology is expected to bethe first human therapeutic protein to achieve FDA approval for marketing in the US this spring.